Flaura2 Phase III Clinical Study Shows Overall Survival Benefit Trend Consistent with Global Data in Chinese Population Treated with Tagrisso and Chemotherapy for EGFR Mutant Advanced Non-Small Cell Lung Cancer
September 19, 2026 — 01:50 CST
This Data Is Locked!
This area is available only to Subscribers.
The analysis of overall survival in the Chinese subgroup of FLAURA2 showed that the benefit-risk profile of the combination regimen was consistent with the global... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
